AbbVie’s third quarter was marked by a positive market reaction, attributed to robust sales growth across its immunology and neuroscience portfolios. Management highlighted the continued momentum of key products like SKYRIZI, RINVOQ, and VRAYLAR, each delivering double-digit revenue increases. CEO Rob Michael emphasized that “nine key products delivered double-digit growth,” with particular strength in immunology and progress in new indications for neuroscience therapies. The quarter’s performance also benefited from newly approved treatments and advancements in product delivery, reflecting strong commercial execution.
Is now the time to buy ABBV? Find out in our full research report (it’s free for active Edge members).
AbbVie (ABBV) Q3 2026 highlights:
- Revenue $17.4 billion vs S&P analysts’ estimates of $17.34 billion (10.3% year-on-year growth, in line)
- Adjusted EPS $3.82 vs S&P analysts’ estimates of $3.77 (1.3% beat)
- Adjusted EPS guidance Management reiterated its full-year adjusted EPS guidance of $13.97 at the midpoint
- Operating margin 36%, up from 12.1% in the same quarter last year
- Market capitalization $521.1 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our top 5 analyst questions from AbbVie’s Q3 earnings call
- Vamil Divan (Guggenheim Securities) asked about growth dynamics for next year and payer discussions for RINVOQ; CEO Rob Michael reiterated robust momentum for SKYRIZI and RINVOQ, while Jeff Stewart outlined stable payer access and minimal rebate changes expected.
- Chris Schott (JPMorgan) questioned the ramp and market share impact of SKYRIZI subcutaneous induction; Executive Vice President Roopal Thakkar and Stewart emphasized rapid share acceleration expected post-approval and differentiation from competitors based on clinical data.
- Louise Chen (Scotiabank) inquired about confidence in emraclidine dosage and underappreciated pipeline assets; Thakkar cited pharmacokinetic data supporting higher dosing and highlighted etentamig and zumilokibart as underestimated opportunities.
- Trung Huynh (RBC) pressed for details on the 340B pilot and TrenibotE resubmission; Michael stressed the importance of transparency in 340B and Thakkar explained the regulatory timeline for TrenibotE, with U.S. resubmission expected soon.
- Terence Flynn (Morgan Stanley) asked about business development strategy and obesity pipeline needs; Michael pointed to bolt-on deals in core areas and Thakkar discussed a focus on differentiated obesity assets, not necessarily requiring GLP-1 drugs.
Catalysts in upcoming quarters
In the coming quarters, the StockStory team will monitor (1) the adoption and uptake of new indications for SKYRIZI and RINVOQ, (2) regulatory progress and potential approvals for key oncology and neuroscience assets, and (3) stabilization trends in the aesthetics portfolio, particularly the rollout of Boey. Additional late-stage clinical trial data and results from combination therapies in immunology will also be important markers of success.
AbbVie currently trades at $294.17, in line with $291.46 just before the earnings. Is there an opportunity in the stock? See for yourself in our full research report (it’s free).
High-quality stocks for all market conditions
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.
